Logo image of HAPB.CA

HAPBEE TECHNOLOGIES-SUB VTG (HAPB.CA) Stock Fundamental Analysis

TSX-V:HAPB - TSX Venture Exchange - CA41136M1023 - Common Stock - Currency: CAD

0.095  -0.01 (-5%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to HAPB. HAPB was compared to 0 industry peers in the Unkown industry. HAPB has a bad profitability rating. Also its financial health evaluation is rather negative. HAPB has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year HAPB has reported negative net income.
HAPB had a negative operating cash flow in the past year.
HAPB had negative earnings in each of the past 5 years.
In the past 5 years HAPB always reported negative operating cash flow.
HAPB.CA Yearly Net Income VS EBIT VS OCF VS FCFHAPB.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

Industry RankSector Rank
ROA -105.57%
ROE N/A
ROIC N/A
ROA(3y)-118.7%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HAPB.CA Yearly ROA, ROE, ROICHAPB.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 1K 2K

1.3 Margins

HAPB's Gross Margin has improved in the last couple of years.
The Profit Margin and Operating Margin are not available for HAPB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.16%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.42%
GM growth 5YN/A
HAPB.CA Yearly Profit, Operating, Gross MarginsHAPB.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 0 -500 -1K -1.5K

More info and screens

0

2. Health

2.1 Basic Checks

HAPB does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for HAPB has been increased compared to 1 year ago.
The debt/assets ratio for HAPB is higher compared to a year ago.
HAPB.CA Yearly Shares OutstandingHAPB.CA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 20M 40M 60M 80M 100M
HAPB.CA Yearly Total Debt VS Total AssetsHAPB.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2M 4M 6M

2.2 Solvency

HAPB has an Altman-Z score of -8.78. This is a bad value and indicates that HAPB is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -8.78
ROIC/WACCN/A
WACC8.81%
HAPB.CA Yearly LT Debt VS Equity VS FCFHAPB.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 2M -2M -4M

2.3 Liquidity

A Current Ratio of 0.88 indicates that HAPB may have some problems paying its short term obligations.
HAPB has a Quick Ratio of 0.88. This is a bad value and indicates that HAPB is not financially healthy enough and could expect problems in meeting its short term obligations.
Industry RankSector Rank
Current Ratio 0.88
Quick Ratio 0.57
HAPB.CA Yearly Current Assets VS Current LiabilitesHAPB.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 1M 2M 3M 4M

More info and screens

1

3. Growth

3.1 Past

HAPB shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.00%.
Looking at the last year, HAPB shows a very negative growth in Revenue. The Revenue has decreased by -56.65% in the last year.
HAPB shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 12.87% yearly.
EPS 1Y (TTM)1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.37%
Revenue 1Y (TTM)-56.65%
Revenue growth 3Y12.87%
Revenue growth 5YN/A
Sales Q2Q%-34.43%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
HAPB.CA Yearly Revenue VS EstimatesHAPB.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 500K 1M 1.5M

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

HAPB reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HAPB.CA Price Earnings VS Forward Price EarningsHAPB.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HAPB.CA Per share dataHAPB.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HAPB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HAPBEE TECHNOLOGIES-SUB VTG

TSX-V:HAPB (7/10/2025, 7:00:00 PM)

0.095

-0.01 (-5%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)05-28 2025-05-28
Earnings (Next)08-25 2025-08-25
Inst Owners0.05%
Inst Owner ChangeN/A
Ins Owners27.86%
Ins Owner ChangeN/A
Market Cap20.01M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 21.45
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.05
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.01
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -105.57%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.16%
FCFM N/A
ROA(3y)-118.7%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.42%
GM growth 5YN/A
F-Score5
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.88
Quick Ratio 0.57
Altman-Z -8.78
F-Score5
WACC8.81%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.37%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-56.65%
Revenue growth 3Y12.87%
Revenue growth 5YN/A
Sales Q2Q%-34.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y18.16%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y51.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y51.36%
OCF growth 3YN/A
OCF growth 5YN/A